Cargando…

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

BACKGROUND: A high-quality programmed cell-death ligand 1 (PD-L1) diagnostic assay may help predict which patients are more likely to respond to anti-programmed cell death-1 (PD-1)/PD-L1 antibody-based cancer therapy. Here we describe a PD-L1 immunohistochemical (IHC) staining protocol developed by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rebelatto, Marlon C., Midha, Anita, Mistry, Amita, Sabalos, Constantine, Schechter, Nicole, Li, Xia, Jin, Xiaoping, Steele, Keith E., Robbins, Paul B., Blake-Haskins, John A., Walker, Jill
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055695/ https://www.ncbi.nlm.nih.gov/pubmed/27717372 http://dx.doi.org/10.1186/s13000-016-0545-8

Ejemplares similares

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay
por: Scorer, Paul, et al.
Publicado: (2018)

Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma
por: Zajac, Magdalena, et al.
Publicado: (2019)

Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation
por: Wildsmith, Sophie, et al.
Publicado: (2022)

Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis
por: Widmaier, Moritz, et al.
Publicado: (2019)

Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies
por: Lawson, Nicola L., et al.
Publicado: (2019)

Correction: Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies
por: Lawson, Nicola L., et al.
Publicado: (2019)

Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in (18)F-FDG PET in Squamous Cell Carcinoma of the Head and Neck
por: Chen, Rui-Yun, et al.
Publicado: (2018)

An immunohistochemical assessment of cellular proliferation markers in head and neck squamous cell cancers.
por: Kearsley, J. H., et al.
Publicado: (1990)

An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma.
por: Vora, A. R., et al.
Publicado: (1997)

Expression of immunohistochemical markers in non-oropharyngeal head and neck squamous cell carcinoma in Ghana
por: Owusu-Afriyie, Osei, et al.
Publicado: (2018)

Optimal PD-L1–high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy
por: Zajac, Magdalena, et al.
Publicado: (2020)

A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer
por: Schabath, Matthew B, et al.
Publicado: (2019)

Correction: Expression of immunohistochemical markers in non-oropharyngeal head and neck squamous cell carcinoma in Ghana
por: Owusu-Afriyie, Osei, et al.
Publicado: (2018)

p16 Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma: Association With Prognostic Parameters
por: Hashmi, Atif A, et al.
Publicado: (2020)

Prognostic value of the immunohistochemical score based on four markers in head and neck squamous cell carcinoma
por: Xu, Qing-Qing, et al.
Publicado: (2023)

Development of an Immunohistochemical Assay for Siglec-15
por: Shafi, Saba, et al.
Publicado: (2022)

Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study
por: Guerini Rocco, Elena, et al.
Publicado: (2022)

Immunohistochemical Expression of Chemokine Receptor CXCR3 and its Ligand CXCL 11 in Basal Cell Carcinoma
por: Ansari, Mariya K., et al.
Publicado: (2023)

Immunohistochemical Expression of Programmed Death Ligand 1 in Oral Extranodal Diffuse Large B Cell Lymphoma
por: Said, Rania Hanafi Mahmoud, et al.
Publicado: (2022)

Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC)
por: Brahmer, Julie, et al.
Publicado: (2014)

Immunohistochemical over expression of p53 in head and neck Squamous cell carcinoma: clinical and prognostic significance
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Assessment of immunohistochemical expression of p16 in head and neck squamous cell carcinoma and their correlation with clinicopathological parameters
por: Pandey, Pinki, et al.
Publicado: (2021)

Effect of Radio-Chemotherapy on PD-L1 Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma
por: Girolami, Ilaria, et al.
Publicado: (2023)

Immunohistochemical detection of the receptor activator of nuclear factor Kappa B ligand and c-fos in giant cell granuloma
por: Ahmed, Atif A, et al.
Publicado: (2016)

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
por: Kelly, Ronan J, et al.
Publicado: (2015)

A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors
por: Papadopoulos, Kyriakos P, et al.
Publicado: (2015)

Deep Semi Supervised Generative Learning for Automated Tumor Proportion Scoring on NSCLC Tissue Needle Biopsies
por: Kapil, Ansh, et al.
Publicado: (2018)

Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status
por: Rizvi, Naiyer, et al.
Publicado: (2015)

Comparison of Immunohistochemical Expression of Antiapoptotic Protein Survivin in Normal Oral Mucosa, Oral Leukoplakia, and Oral Squamous Cell Carcinoma
por: Negi, Amita, et al.
Publicado: (2015)

Angioleiomyomas in the head and neck: A retrospective clinical and immunohistochemical analysis
por: LIU, YING, et al.
Publicado: (2014)

Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET
por: Grönroos, Tove J, et al.
Publicado: (2014)

The correlations between dynamic contrast enhanced magnetic resonance imaging and immunohistochemical data in head and neck squamous cell carcinomas
por: KARABAY, Nuri, et al.
Publicado: (2022)

A TRAIL-R1-specific ligand in combination with doxorubicin selectively targets primary breast tumour cells for apoptosis
por: Twiddy, D, et al.
Publicado: (2010)

Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas
por: El Samman, Dina Mohamed, et al.
Publicado: (2021)

Merkel cell carcinoma with an unusual immunohistochemical profile
por: Pilloni, L., et al.
Publicado: (2009)

Immunohistochemical characterization of neoplastic cells of breast origin
por: Noriega, MariadelasMercedes, et al.
Publicado: (2012)

Immunohistochemical studies of adult human glial cells
por: Grenier, Yannick, et al.
Publicado: (1989)

Quantification of Immunohistochemically Stained Cells in Skin Biopsies
por: Emmanuel, Thomas, et al.
Publicado: (2022)

Immunohistochemical analysis and correlation of cyclooxygenase-2 expression status with clinicopathological parameters in head and neck squamous cell carcinomas: An Indian perspective
por: Chadha, Prerna, et al.
Publicado: (2020)

Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis
por: Guo, Xiang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0tqlolurpqclihkl7r526alfs8